“I am convinced that the mRNA vaccine against melanoma will definitely arrive at a recording. The times will not be long, there is a registration study underway, but it will take at least 3 years”. Giuseppe Curigliano, professor of medical oncology at the University of Milan, explains this to Adnkronos Salute on the sidelines of the presentation of the 4th Italian Summit On Precision Medicine, an event that opens today in Rome organized by the Foundation for Personalized Medicine (Fmp).
“This technology will also have an impact on two other pathologies, lung cancers and triple-negative breast cancers, on which there will soon be studies”, continues Curigliano, recalling that we have seen the benefits of this very innovative methodology “developed for vaccines, against Covid And in some oncological diseases it will certainly make a strong contribution.”
In Italy every year 31 thousand cases of cancer due to genetic alterations
Every year in Italy over 31 thousand new cases of cancer are linked to alterations in genes involved in the onset and development of neoplasms. For this reason it is necessary to adopt new technologies to perform genetic tests more efficiently, with a reduction in test execution times and less inconvenience for patients and their families. And it is necessary to improve the “personalization” of anti-tumor diagnostic and therapeutic tools, highlights Summiot.
“Precision medicine is a surprising innovation and must change our approach to over 200 oncological diseases”, explains Paolo Marchetti, president of the Foundation for Personalized Medicine (Fmp), presenting the meeting.
#Cancer #years #melanoma #vaccine #oncologist39s #prediction
